terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026

EVA LIVE TARGETS A $3 TRILLION GLOBAL DEFENSE, SATELLITE AND AI INFRASTRUCTURE OPPORTUNITY WITH PROPOSED ACQUISITION OF AIRBEAM WIRELESS TECHNOLOGIES

View original at globenewswire.com
EVA LIVE TARGETS A $3 TRILLION GLOBAL DEFENSE, SATELLITE AND AI INFRASTRUCTURE OPPORTUNITY WITH PROPOSED ACQUISITION OF AIRBEAM WIRELESS TECHNOLOGIES Proposed acquisition brings access to more than 260 patents and advanced millimeter-wave semiconductor technology built upon a technology lineage that benefited from more…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Airbeam's technology, built on more than 260 patents and a lineage that benefited from over $150 million in engineering and innovation over two decades, gives Eva Defense the opportunity to build the communications backbone for autonomous drone swarms, resilient military networks, smart cities, satellite constellations and eventually infrastructure beyond Earth.

    60% confidence
  • According to Airbeam's historical documentation, the technology lineage represented by its acquired assets traces back more than two decades and benefited from more than $150 million in cumulative research, development and commercialization investment.

    60% confidence
  • Eva Live believes autonomous defense systems, AI communications infrastructure, and satellite networking collectively represent a $3 trillion global opportunity over the coming decades.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com